

IN THE SPECIFICATION:

Please replace paragraph [0011] on pages 3-4 with :

[0011]

Thus, the present invention provides a polypeptide comprising the amino acid sequence of SEQ ID NO: 1 as well as a polypeptide having at least 80% homology to the amino acid sequence of SEQ ID NO: 1; having an amino acid sequence, wherein at least an amino acid residue at position 39, ~~84~~ 85, 296, or 300 from the N-terminus is Ala, an amino acid residue at position ~~85~~ 86 or 310 is Thr, an amino acid residue at position 163 or ~~333~~ 303 is Ser, an amino acid residue at position 195 or 257 is Leu, an amino acid residue at position 271 is Arg, an amino acid residue at position 297 is Asp, an amino acid residue at position 299 is Gly, an amino acid residue at position 313 is Pro, or an amino acid residue at position 316 is Val, in correspondence with the amino acid sequence of SEQ ID NO: 1; and having immunogenicity inducing the production of an antibody against the polypeptide comprising the amino acid sequence of SEQ ID NO: 1. The polypeptides include those isolated.

Please replace paragraph [0012] on page 4 with:

[0012]

In addition, the present invention provides a polypeptide fragment having a partial sequence of the amino acid sequence of SEQ ID NO: 1; or a partial sequence of an amino acid sequence having at least 80% homology to the amino acid sequence of SEQ ID NO: 1, wherein at least an amino acid residue at position 39, ~~84~~ 85, 296, or 300 from the N-terminus is Ala, an amino acid residue at position ~~85~~ 86 or 310 is Thr, an amino acid residue at position 163 or ~~333~~ 303 is Ser, an amino acid residue at position 195 or 257 is

Leu, an amino acid residue at position 271 is Arg, an amino acid residue at position 297 is Asp, an amino acid residue at position 299 is Gly, an amino acid residue at position 313 is Pro, or an amino acid residue at position 316 is Val, in correspondence with the amino acid sequence of SEQ ID NO: 1; and having immunogenicity inducing the production of an antibody against the polypeptide comprising the amino acid sequence of SEQ ID NO: 1. The polypeptide fragment includes those isolated.

Please replace paragraph [0016] on pages 4-5 with:

[0016]

Furthermore, the present invention provides a polynucleotide coding for a polypeptide comprising the amino acid sequence of SEQ ID NO: 1 as well as a polynucleotide coding for a polypeptide having at least 80% homology to the amino acid sequence of SEQ ID NO: 1; having an amino acid sequence, at least an amino acid residue at position 39, ~~84~~ 85, 296, or 300 from the N-terminus is Ala, an amino acid residue at position ~~85~~ 86 or 310 is Thr, an amino acid residue at position 163 or ~~333~~ 303 is Ser, an amino acid residue at position 195 or 257 is Leu, an amino acid residue at position 271 is Arg, an amino acid residue at position 297 is Asp, an amino acid residue at position 299 is Gly, an amino acid residue at position 313 is Pro, or an amino acid residue at position 316 is Val, in correspondence with the amino acid sequence of SEQ ID NO: 1; and having immunogenicity inducing the production of an antibody against the polypeptide comprising the amino acid sequence of SEQ ID NO: 1.

Please replace paragraph [0017] on page 5 with:

[0017]

Moreover, the present invention provides a polynucleotide coding for a polypeptide fragment having a partial sequence of the amino acid sequence of SEQ ID NO: 1; or a partial sequence of an amino acid sequence having at least 80% homology to the amino acid sequence of SEQ ID NO: 1, wherein at least an amino acid residue at position 39, ~~84~~ 85, 296, or 300 from the N-terminus is Ala, an amino acid residue at position ~~85~~ 86 or 310 is Thr, an amino acid residue at position 163 or ~~333~~ 303 is Ser, an amino acid residue at position 195 or 257 is Leu, an amino acid residue at position 271 is Arg, an amino acid residue at position 297 is Asp, an amino acid residue at position 299 is Gly, an amino acid residue at position 313 is Pro, or an amino acid residue at position 316 is Val, in correspondence with the amino acid sequence of SEQ ID NO: 1; and having immunogenicity inducing the production of an antibody against the polypeptide comprising the amino acid sequence of SEQ ID NO: 1.

Please replace paragraph [0021] on pages 5-6 with:

[0021]

Moreover, the present invention provides an RNA molecule consisting of the nucleotide sequence of ~~SEQ ID NO: 3~~ SEQ ID NO: 10 as well as an RNA molecule consisting of a mutant nucleotide sequence of the nucleotide sequence of ~~SEQ ID NO: 3~~ SEQ ID NO: 10 with the addition, deletion, or substitution of at least one base, and suppressing the expression of a protein specific to human liver cancer.

Please replace paragraph [0026] on pages 6-7 with:

[0026]

Figure 1 is a graph showing the expression level of Pim-3 in an HBsTg mouse;

~~Figure 2 shows the polynucleotide sequence of hPim-3 and its corresponding polypeptide sequence~~ Figure 2A shows the polynucleotide sequence of hPim-3 and its corresponding polypeptide sequence;

Figure 2B shows the polynucleotide sequence of hPim-3 and its corresponding polypeptide sequence;

Figure 3 is a diagram where the amino acid sequences of Pim-3 are compared among a human, a mouse, and a rat;

Figure 4 is a diagram where amino acid sequences are compared among human Pim-1, Pim-2, and Pim-3;

Figure 5 is a diagram showing hPim-3 and GAPDH mRNA expression in human normal tissue;

Figure 6 is a diagram showing human Pim-3 mRNA expression in a human liver cancer cell line;

Figure 7 is a diagram specifically showing hPim-3 expression in human liver cancer tissue;

Figure 8 is a graph showing a decrease in the survival activity of a human liver cancer cell, which was transfected with the siRNA of hPim-3;

Figure 9 is a diagram showing that cells started to exfoliate in the treated group on the 4th day and subsequent days of transfection of the siRNA of hPim-3; and

Figure 10 is a graph showing changes in the cell cycle of a human liver cancer cell in which the siRNA of Pim-3 was introduced.

Please replace paragraph [0031] on pages 7-8 with:

[0031]

As shown in Figure 3, the amino acid sequence (SEQ ID NO: 1) of a human Pim-3 protein, the polypeptide specific to liver cancer of the present invention, has the following characteristic points of difference, when compared with those of rat and mouse Pim-3 proteins: the amino acid sequence of SEQ ID NO: 1 differs from those of the rat and mouse Pim-3 proteins, in that the amino acid residues at positions 39, ~~84~~ 85, 296, and 300 from the N-terminus are Ala, the amino acid residue at position ~~85~~ 86 or 310 is Thr, the amino acid residues at positions 163 and ~~333~~ 303 are Ser, the amino acid residues at position 195 and 257 are Leu, the amino acid residue at position 271 is Arg, the amino acid residue at position 297 is Asp, an amino acid residue at position 299 is Gly, the amino acid residue at 313 is Pro, and the amino acid residue at position 316 is Val.

Please replace paragraph [0032] on page 8 with:

[0032]

Thus, the polypeptide homologue of the present invention is a polypeptide having at least 80% homology to the amino acid sequence of SEQ ID NO: 1; having an amino acid sequence, wherein at least an amino acid residue at position 39, ~~84~~ 85, 296, or 300 from the N-terminus is Ala, an amino acid residue at position ~~85~~ 86 or 310 is Thr, an amino acid residue at position 163 or ~~333~~ 303 is Ser, an amino acid residue at position 195 or 257 is Leu, an amino acid residue at position 271 is Arg, an amino acid residue at position 297 is Asp, an amino acid residue at position 299 is Gly, an amino acid residue at position 313 is Pro, or an amino acid residue at position 316 is Val, in correspondence with the amino acid sequence of SEQ ID NO: 1; and having immunogenicity inducing

the production of an antibody against a polypeptide comprising the amino acid sequence of SEQ ID NO: 1. The homology of the homologue is especially 90%, preferably 95%, particularly preferably 97%.

Please replace paragraph [0033] on page 8 with:

[0033]

The peptide fragment of the specific polypeptide of the present invention is a polypeptide fragment having a partial sequence of the amino acid sequence of SEQ ID NO: 1; or a partial sequence of an amino acid sequence having at least 80% homology to the amino acid sequence of SEQ ID NO: 1, wherein at least an amino acid residue at position 39, ~~84~~ 85, 296, or 300 from the N-terminus is Ala, an amino acid residue at position ~~85~~ 86 or 310 is Thr, an amino acid residue at position 163 or ~~333~~ 303 is Ser, an amino acid residue at position 195 or 257 is Leu, an amino acid residue at position 271 is Arg, an amino acid residue at position 297 is Asp, an amino acid residue at position 299 is Gly, an amino acid residue at position 313 is Pro, or an amino acid residue at position 316 is Val, in correspondence with the amino acid sequence of SEQ ID NO: 1; and having immunogenicity inducing the production of an antibody against the polypeptide comprising the amino acid sequence of SEQ ID NO: 1.

Please replace paragraph [0035] on page 9 with:

[0035]

In the present specification, the N-terminuses (amino terminuses) of the ~~polynucleotide~~ polypeptide, the homologue, and the polypeptide fragment (hereinafter, abbreviated to the ~~polynucleotide~~ polypeptide and so on, if necessary) are indicated in the left, and the C terminuses (carboxyl terminuses) thereof are indicated in the right, in

accordance with the standard notation. The polypeptide of the present invention can have a carboxyl group (-COOH), carboxylate (-COO-), amide (-CONH₂), or ester (-COOR) at the C terminus. Examples of the side chain R of this ester include: C₁ to C₆ alkyl groups such as methyl, ethyl, n-propyl, isopropyl, and n-butyl; C₃ to C₈ cycloalkyl groups such as cyclopentyl and cyclohexyl; C₆ to C₁₂ aryl groups such as phenyl and α -naphthyl; and alkyl groups such as phenyl-C₁ to -C₂ alkyl groups such as benzyl and phenethyl or α -naphthyl-C₁ to -C₂ alkyl groups such as α -naphthylmethyl.

Please replace paragraph [0075] on page 18 with:

[0075]

The RNA molecule of the present invention may be an RNA molecule consisting of the nucleotide sequence of ~~SEQ ID NO: 3~~ SEQ ID NO:10, or an RNA molecule consisting of a mutant nucleotide sequence of the nucleotide sequence of ~~SEQ ID NO: 3~~ SEQ ID NO:10 with the addition, deletion, or substitution of at least one base, and suppressing the expression of a protein specific to human liver cancer. The RNA molecule (siRNA) can be designed on the basis of the sequence of polynucleotide of the present invention according to a method known in the art (e.g., Nature, Vol. 411, pp. 494, 2001).

Please replace paragraph [0108] on page 25 with:

[0108]

In addition, the amino acid sequence (SEQ ID NO: 1) obtained from the ORF had high identity (95.0%) to those of mouse and rat Pim-3 ~~polynucleotides~~ polypeptides (Figure 3). Based on these results, the present inventors judged the clone human Pim-3 cDNA.

After the Abstract and before the Drawings, please insert the following Sequence

Listing:

SEQUENCE LISTING

<110> Kureha Chemical Industry Company Limited

MUKAIDA, Naofumi

FUJII, Chifumi

<120> Polypeptide associated with hepatocellular carcinoma, polynucleotide encoding the polypeptide and RNA molecule suppressing the polypeptide expression

<130> 0701011WO1

<160> 11

<170> PatentIn version 3.1

<210> 1

<211> 326

<212> PRT

<213> Homo sapiens

<400> 1

Met Leu Leu Ser Lys Phe Gly Ser Leu Ala His Leu Cys Gly Pro Gly
1 5 10 15

Gly Val Asp His Leu Pro Val Lys Ile Leu Gln Pro Ala Lys Ala Asp
20 25 30

Lys Glu Ser Phe Glu Lys Ala Tyr Gln Val Gly Ala Val Leu Gly Ser
35 40 45

Gly Gly Phe Gly Thr Val Tyr Ala Gly Ser Arg Ile Ala Asp Gly Leu
50 55 60

Pro Val Ala Val Lys His Val Val Lys Glu Arg Val Thr Glu Trp Gly
65 70 75 80

Ser Leu Gly Gly Ala Thr Val Pro Leu Glu Val Val Leu Leu Arg Lys
85 90 95

Val Gly Ala Ala Gly Gly Ala Arg Gly Val Ile Arg Leu Leu Asp Trp
100 105 110

Phe Glu Arg Pro Asp Gly Phe Leu Leu Val Leu Glu Arg Pro Glu Pro
115 120 125

Ala Gln Asp Leu Phe Asp Phe Ile Thr Glu Arg Gly Ala Leu Asp Glu
130 135 140

Pro Leu Ala Arg Arg Phe Phe Ala Gln Val Leu Ala Ala Val Arg His
145 150 155 160

Cys His Ser Cys Gly Val Val His Arg Asp Ile Lys Asp Glu Asn Leu
165 170 175

Leu Val Asp Leu Arg Ser Gly Glu Leu Lys Leu Ile Asp Phe Gly Ser
180 185 190

Gly Ala Leu Leu Lys Asp Thr Val Tyr Thr Asp Phe Asp Gly Thr Arg
195 200 205

Val Tyr Ser Pro Pro Glu Trp Ile Arg Tyr His Arg Tyr His Gly Arg
 210 215 220

Ser Ala Thr Val Trp Ser Leu Gly Val Leu Leu Tyr Asp Met Val Cys
 225 230 235 240

Gly Asp Ile Pro Phe Glu Gln Asp Glu Glu Ile Leu Arg Gly Arg Leu
 245 250 255

Leu Phe Arg Arg Arg Val Ser Pro Glu Cys Gln Gln Leu Ile Arg Trp
 260 265 270

Cys Leu Ser Leu Arg Pro Ser Glu Arg Pro Ser Leu Asp Gln Ile Ala
 275 280 285

Ala His Pro Trp Met Leu Gly Ala Asp Gly Gly Ala Pro Glu Ser Cys
 290 295 300

Asp Leu Arg Leu Cys Thr Leu Asp Pro Asp Asp Val Ala Ser Thr Thr
 305 310 315 320

Ser Ser Ser Glu Ser Leu
 325

<210> 2

<211> 2392

<212> DNA

<213> Homo sapiens

<400> 2

agcggaccga cgcgacacgc cgtgcgcctc cgcggctgcg ctacgaaaac gagtcccgga 60
 gcggccccgc gcccgcgcga cccggccctc gcccaccgga agacaggcgc ccagctgccc 120
 cgccgtctcc ccagctagcg cccggccgcc gccgcctcgc gggccccggg cggaaggggg 180
 cggggtcccg attcgccccg ccccgcgga gggatacgcg gcgccgcggc caaaacccc 240
 cgggcgaggc ggccggggcg ggtgaggcgc tccgcctgct gctcgtctac gcggtccccg 300

cgggccttcc gggcccactg cgccgcgcgg accgcctcgg gctcggacgg ccggtgtccc 360
 cggcgcgcgg ctcgccgga tcggccgcgg ctccggcgcc tggggctcgg ggctccgggg 420
 aggccgtcgc ccgcgatgt gctctcaag ttcggctccc tggcgacact ctgcggggccc 480
 ggcggcgtgg accacctccc ggtgaagatc ctgcagccag ccaaggcgga caaggagagc 540
 ttcgagaagg cgtaccaggt gggcgccgtg ctgggtagcg gcggcttcgg cacggtctac 600
 gcgggtagcc gcatcgccga cgggctccc gtggctgtga agcacgtggt gaaggagcgg 660
 gtgaccgagt ggggcagcct gggcggcgcg accgtgcccc tggaggtggt gctgctgcgc 720
 aagggtgggcg cggcggggcg cgcgcgcggc gcatccgcc tgctggactg gttcagcgg 780
 cccgacggct tctgtgtgt gctggagcgg cccgagccgg cgcaggacct ctccgacttt 840
 atcacggagc gcggcgccct ggacgagccg ctggcgcgcc gcttcttcgc gcaggtgtg 900
 gccgccgtgc gccactgcca cagctgcggg gtcgtgcacc gcgacattaa ggacgaaaat 960
 ctgcttgtgg acctgcgtc cggagagctc aagctcatcg acttcggttc ggggtgcgtg 1020
 ctcaaggaca cgtctacac cgacttcgac ggcacccgag tgtacagccc cccggagtgg 1080
 atccgtacc accgtacca cggcgctcg gccaccgtgt ggtcgtggg cgtgcttctc 1140
 tacgatattg tgttgggga catcccttc gagcaggacg aggagatcct ccgaggccgc 1200
 ctgctctcc ggaggagggt ctctccagag tgccagcagc tgatccggtg gtgcctgtcc 1260
 ctgcggccct cagagcggcc gtcgtggat cagattgcgg cccatccctg gatgtgggg 1320
 gctgacgggg gcgccccgga gagctgtgac ctgcggctgt gcaccctga cctgatgac 1380
 gtggccagca ccacgtccag cagcgagagc ttgtaggag ctgcacctga ctgggagcta 1440
 ggggaccacc tgccttgcc agacctggga cggcccgaga cctgacttt ttctgcgtg 1500
 ggccgtctcc tctgcggaa gcagtacct ctgacctg gtgaccttcg ctttgagtgc 1560
 ctttgaacg ctggtccgc gggacttgg ttctcaagc tctgtctgc caaagacgt 1620
 ccggtcgagg tccgcctgc cctgggtgga tacttgaacc ccagacgcc ctctgtgtg 1680
 ctgtgtccgg aggcggcctt cccatctgcc tgcccccg gagctcttc cgccggcgca 1740
 ggggtccaag cccacctccc gccctcagtc ctgcggtgt cgtctgggca cgtctgcac 1800
 acacaatgca agtctggcc tccgcgccc cccgcccacg cgagccgtac ccgccgcaa 1860
 ctctgttatt tatgtgtga cccctggag gtgccctcg cccaccggg ctattattg 1920
 ttaatttat ttgtgaggt tatttctct gagcagctg cctctccaa gcccagggg 1980
 acagtgggga ggcaggggag ggggtggctg tggccaggg accccaggcc ctgattctg 2040
 tgcctggcgt ctgtctggc cccgcctgtc agaagatgaa catgtatgt ggctaactta 2100

aggggagtggtg gtagccctga cacttccagg cactgtgcc agggtttggg tttaaatta 2160
 ttgactttgt acagtctgct tgtgggctct gaaagctggg gtggggccag agcctgagcg 2220
 ttaatttat tcagtacctg tgtttgtgtg aatgcggtgt gtgcaggcat cgcagatggg 2280
 ggttcttca gttcaaaagt gagatgtctg gagatcatat tttttatac aggtatttca 2340
 attaaaatgt tttgtacat aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aa 2392

<210> 3

<211> 28

<212> DNA

<213> Artificial sequence

<220>

<223> Pim-3 sense primer

<400> 3

aagcagtgc ctctgacccc tggtagcc 28

<210> 4

<211> 25

<212> DNA

<213> Artificial sequence

<220>

<223> Pim-3 antisense primer

<400> 4

cagcggaacc gctcattgcc aatgg 25

<210> 5

<211> 20

<212> DNA

<213> Artificial sequence

<220>

<223> GAPDH sense prime

<400> 5

accacagtcc atgcatcac

20

<210> 6

<211> 20

<212> DNA

<213> Artificial sequence

<220>

<223> GAPDH antisense primer

<400> 6

tccaccaccc tgggtgta

20

<210> 7

<211> 20

<212> DNA

<213> Artificial sequence

<220>

<223> Probe used in first screening of hPim-3

<400> 7

ctgtgaagca cgtggtgaag

20

<210> 8

<211> 19

<212> PRT

<213> Artificial sequence

<220>

<223> Epitop used in the production of antibody to hPim-3 polypeptide

<400> 8

Cys Gly Pro Gly Gly Val Asp His Leu Pro Val Lys Ile Leu Gln Pro

1 5 10 15

Ala Lys Ala

<210> 9

<211> 21

<212> DNA

<213> Artificial sequence

<220>

<223> Targeted mRNA

<400> 9

gcacgtggtg aaggagcgcg g

21

<210> 10

<211> 21

<212> RNA

<213> Artificial sequence

<220>

<223> siRNA in example 9

<400> 10
ccgcgcuccu ucaccacgug c

21

<210> 11

<211> 19

<212> RNA

<213> Artificial sequence

<220>

<223> Random RNA fragment

<400> 11
gcgcgcuuug uaggauucg